 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
 | |
| Industry | |
|---|---|
| Founded | 2003 |
| Fate | Acquired by Roche Pharmaceuticals |
| Headquarters | Copenhagen, Denmark |
| Products | RNA-targeted medicines, Locked nucleic acid (LNA) based drugs |
Santaris Pharma A/S was a biopharmaceutical company founded in 2003 in Copenhagen, Denmark.[1] The company also had a branch in San Diego, California that opened in 2009.[2] Created by a merger between Cureon and Pantheco, Santaris developed RNA-targeted medicines using a Locked Nucleic Acid (LNA) Drug Platform and Drug Development Engine.[3]
Santaris had gained intellectual property rights to the therapeutic applications of locked nucleic acid (LNA) technology. These rights included ownership of several patents, mostly with the chemistry and manufacturing of therapeutic drugs. With its LNA technology, Santaris developed drugs for the treatment of cancers and tumours using microRNA and mRNA. Its research focused on infectious diseases and metabolic disorders. The company also worked on collaborations with other pharmaceutical companies to develop drugs that could treat cancers and rare genetic disorders, among other things.[3]
In August 2014, Santaris was acquired by Roche for $450 million. As a result, the Copenhagen site was renamed the Roche Innovation Center Copenhagen (RICC).[4] RICC houses Roche's RNA Molecule Research, which is part of Roche Pharma Research and Early Development.[5] In 2023, it was closed due to a decision to move research to Basel, Switzerland where Roche is headquartered.[6] The former employees of the RICC were offered new jobs at the Danish pharmaceutical company Novo Nordisk.[7]
- ^ "Santaris Pharma - 2008 Fierce 15". Fierce Biotech. June 2008.
- ^ "MicroRNA Drug Developer Santaris Establishes Toehold in San Diego With Isis Veteran". Xconomy. September 16, 2009. Archived from the original on 2021-05-12.
- ^ a b "Developing LNA technology for new-generation cancer drugs" (PDF). SP2 Magazine. March 2006.
- ^ "Forbion Announces Sale of Portfolio Company, Santaris Pharma, to Roche for up to $450m". www.businesswire.com. 2014-08-04. Retrieved 2022-03-05.
- ^ "Roche | Pharma R&D - Copenhagen, Denmark". www.roche-dot-com-staging.cwp.roche.com. Retrieved 2024-05-12.
- ^ "Roche to close Danish research center with 60 workers". medwatch.com. 2022-10-26. Archived from the original on 2023-02-15. Retrieved 2024-05-31.
- ^ "Roche opens Novo Nordisk career path for laid-off employees". medwatch.com. 2022-12-19. Retrieved 2024-05-31.